Percutaneous absorption VC ethyl ether liposome emulsion as well as preparation method and application thereof

By combining transdermal absorption liposome lotion formed by VC ethyl ether and other active substances, the problem of deterioration of vitamin C ethyl ether stability is solved, the effect of effectively inhibiting melanin formation and skin protection is achieved, and whitening is improved and antioxidant capacity.

CN118948662AInactive Publication Date: 2024-11-15WANG SHUHE BIOMEDICINE (WUHAN) CO LTD
View PDF 10 Cites 0 Cited by

Patent Information

Application Number
CN202411008670.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Vitamin C ethyl ether has poor stability when combined with other substances, resulting in a weakening effect of inhibiting melanin formation.

Method used

Using transdermal absorption of VC ethyl ether liposome emulsion, multi-components are formed by combining VC ethyl ether with active substances such as resveratrol, tetraisopalmitate ascorbic acid, ergothioneine, lipids, etc. Liposomes use the complementary mechanisms of action between multiple active substances to improve the overall effectiveness of the product, and form a stable liposome emulsion through specific preparation methods such as sonication, shearing and homogeneous circulation treatment.

Benefits of technology

Improve the stability of VC ethyl ether, significantly inhibit melanin formation, effectively inhibit tyrosinase activity, inhibit melanoma cell proliferation, eliminate free radicals, and have whitening, antioxidant, anti-inflammatory, and anti-aging effects, improving the skin stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948662A_ABST
    Figure CN118948662A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of lipidosome, in particular to a transdermally absorbed VC ethyl ether lipidosome emulsion as well as a preparation method and application thereof. The transdermally absorbed VC ethyl ether liposome emulsion provided by the invention comprises a component A, a component B and a component C, the component A is prepared from VC (Vitamin C) ethyl ether, resveratrol ascorbyl tetraisopalmitate, ergothioneine and lipid; the component B comprises VC ethyl ether, a film-forming agent and a co-emulsifier; the component C comprises an emulsifier and an oil phase pre-prepared system; the oil phase pre-preparation system is composed of caprylic acid triglyceride and triglyceride. All the components of the liposome emulsion provided by the invention have a synergistic effect, so that the liposome emulsion has good stability and can effectively inhibit the activity of tyrosinase and inhibit the proliferation of melanoma cells.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of liposomes, and in particular to a transdermal VC ethyl ether liposome emulsion and a preparation method and application thereof. Background Art

[0002] Vitamin C ethyl ether (3-O-Ethyl-L-ascorbic acid), also known as VC ethyl ether, is a non-discoloring vitamin C derivative that can inhibit the formation of melanin. Compared with vitamin C, vitamin C ethyl ether can improve the utilization of vitamin C and has a whitening effect. In the field of cosmetic technology, VC ethyl ether can be used as an active ingredient to enhance the whitening effect. However, when VC ethyl ether is used as an active substance in combination with other substances, there is a problem of poor stability, which leads to a weakening of its effect of inhibiting the formation of melanin. Summary of the invention

[0003] The invention discloses a transdermal VC ethyl ether liposome emulsion and a preparation method and application thereof, thereby solving the technical problem that the stability of VC ethyl ether is poor when used as an active substance in combination with other substances.

[0004] In order to solve the above technical problems, the present invention provides a transdermal VC ethyl ether liposome emulsion in the first aspect. The transdermal VC ethyl ether liposome emulsion comprises component A, component B and component C;

[0005] The component A comprises, by weight:

[0006] 3-10 parts of VC ethyl ether, 3-10 parts of resveratrol, 0.5-2.5 parts of ascorbyl tetraisopalmitate, 2-5 parts of ergothioneine, 4-14 parts of lipids;

[0007] The B component comprises, by weight:

[0008] 5-20 parts of VC ethyl ether, 1.5-6 parts of film former, 65-140 parts of auxiliary emulsifier;

[0009] The C component comprises, by weight:

[0010] 6-16 parts of emulsifier, 30-60 parts of oil phase pre-formulated system;

[0011] The oil phase preformulation system consists of caprylic acid triglyceride and triglyceride.

[0012] In some embodiments, the transdermal VC ethyl ether liposome emulsion comprises component A, component B and component C;

[0013] The component A comprises, by weight:

[0014] 5 parts of VC ethyl ether, 5 parts of resveratrol, 1 part of ascorbyl tetraisopalmitate, 3 parts of ergothioneine, 8 parts of lipids;

[0015] The B component comprises, by weight:

[0016] 10 parts of VC ethyl ether, 3 parts of film former, 100 parts of co-emulsifier;

[0017] The C component comprises, by weight:

[0018] 10 parts of emulsifier, 40 parts of oil phase pre-formulated system;

[0019] The oil phase pre-formulated system consists of caprylic acid triglyceride and triglyceride in a mass ratio of 1:1.

[0020] In some embodiments, the lipid is one or more of lecithin, cholesterol, soybean lecithin, hydrogenated lecithin, egg yolk lecithin, phosphatidylcholine, and phosphatidylserine;

[0021] And / or, the film-forming agent is one or more of hydroxyethyl cellulose, acrylic acid-acrylate copolymer, L-arabinose, and pullulan.

[0022] And / or, the auxiliary emulsifier is one or more of glycerol, 1,3-propylene glycol, butylene glycol, 1,2-pentanediol, sorbitol, 1,2-hexanediol, dipropylene glycol, butylene glycol laureth-23, PPG-26-butylene glycol polyether-26, trideceth-12, and hexyldecanol;

[0023] And / or, the emulsifier is one or more of polyoxyethylene hydrogenated castor oil, coco-glucoside, cetearyl alcohol polyether, polyglyceryl-10 stearate, PEG-8 caprylic / capric glyceride, sucrose stearate, sodium alkylbenzene sulfonate, and PEG-40 hydrogenated castor oil.

[0024] In a second aspect, the present invention provides a method for preparing the transdermal VC ethyl ether liposome emulsion, comprising the following steps:

[0025] Dissolving the VC ethyl ether, the resveratrol, the ascorbyl tetraisopalmitate, the ergothioneine and the lipid in an organic solvent to obtain the A component;

[0026] The VC ethyl ether, the film-forming agent and the co-emulsifier are uniformly mixed to obtain the B component;

[0027] Adding the emulsifier to the oil phase preformulation system to obtain the C component;

[0028] adding the B component to the A component to obtain liposome colostrum;

[0029] The C component is added to the liposome colostrum, and the mixture is subjected to stirring, shearing, ultrasonication, homogenization circulation treatment and cooling to room temperature to obtain the transdermal VC ethyl ether liposome emulsion.

[0030] In some embodiments, the preparation conditions of the A component are: ultrasonic treatment at 45-56° C. for 30-50 min;

[0031] And / or, the preparation conditions of the B component are: stirring at 400-600 rpm for 30-40 min at 45-55°C;

[0032] And / or, the preparation conditions of the C component are: stirring at 400-600 rpm for 25-40 min at 40-50° C.;

[0033] And / or, the preparation conditions of the liposome colostrum are: shearing at a shear rate of 7000-8500 rpm for 8-15 min;

[0034] And / or, the number of cycles of the homogenization cycle treatment is 4-6 times.

[0035] The present invention provides, in a third aspect, the use of the transdermal VC ethyl ether liposome emulsion in the preparation of antioxidants and / or melanoma cell inhibitors.

[0036] In some embodiments, the transdermal VC ethyl ether liposome emulsion is used to scavenge free radical activity;

[0037] And / or, the transdermal VC ethyl ether liposome emulsion is used to inhibit melanoma cell proliferation.

[0038] In some embodiments, the transdermal VC ethyl ether liposome emulsion can also be used to inhibit tyrosinase activity.

[0039] In a fourth aspect, the present invention provides a use of the transdermal VC ethyl ether liposome emulsion in the preparation of cosmetics.

[0040] The present invention provides a cosmetic in a fourth aspect, comprising the transdermal VC ethyl ether liposome emulsion.

[0041] Compared with the prior art, the present invention has the following beneficial effects:

[0042] The VC ethyl ether liposome emulsion for transdermal absorption provided by the present invention improves the stability of VC ethyl ether by compounding the active substance VC ethyl ether with resveratrol, ascorbyl tetraisopalmitate, ergothioneine, lipid, emulsifier, etc., and can effectively inhibit the formation of melanin. The VC ethyl ether liposome emulsion for transdermal absorption adopts a strategy of combining multiple active substances to utilize the complementary action mechanisms between active substances, improve the overall efficacy of the product, and adjust the skin state from multiple angles. The particle size of the VC ethyl ether liposome emulsion for transdermal absorption is 34.3-37.3nm, showing good stability, and can enhance the effect of transdermal absorption of VC ethyl ether, can effectively inhibit tyrosinase activity, inhibit melanoma cell proliferation, scavenge free radicals, comprehensively protect the skin, and has whitening, anti-oxidation, anti-inflammatory, anti-aging and other effects, and can maintain the skin barrier function, improve skin redness, and improve skin stability. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.

[0044] Figure 1 This is a graph showing the results of an ABTS free radical scavenging experiment provided in Experimental Example 2 of the present invention.

[0045] Figure 2 This is a graph showing the results of a tyrosinase activity inhibition experiment provided in Experimental Example 3 of the present invention.

[0046] Figure 3 This is a graph showing the experimental results of inhibiting melanin formation provided in Experimental Example 4 of the present invention.

[0047] Figure 4 This is a graph showing the experimental results of an in vitro transdermal absorption test provided in Experimental Example 5 of the present invention.

[0048] Figure 5 This is an observation diagram of the mouse skin irritation experiment provided in Application Example 1 of the present invention. DETAILED DESCRIPTION

[0049] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the raw materials, components, solvents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.

[0050] The technical solution of the present invention will be further described below in conjunction with specific embodiments.

[0051] Example 1

[0052] This example provides an experiment for preparing a transdermal VC ethyl ether liposome emulsion.

[0053] Dissolve 5 parts of VC ethyl ether, 5 parts of resveratrol, 1 part of ascorbyl tetraisopalmitate (VC-IP), 3 parts of ergothioneine, 4 parts of soybean lecithin, 2 parts of egg yolk lecithin and 2 parts of cholesterol in 100 parts of anhydrous ethanol to obtain a mixed solution; then ultrasonicate the mixed solution at a temperature of 50° C. for 30 minutes to make it uniformly dispersed, and then perform thin film rotary evaporation to form a film to remove anhydrous ethanol, so as to obtain a film containing VC ethyl ether;

[0054] 10 parts of VC ethyl ether, 1 part of hydroxyethyl cellulose, 2 parts of acrylic acid-acrylate copolymer, 50 parts of glycerol, 30 parts of 1,3-propylene glycol and 20 parts of butylene glycol were mixed, and stirred at 50°C and 500 rpm for 30 minutes to form a uniform aqueous phase;

[0055] 6 parts of polyoxyethylene hydrogenated castor oil, 2 parts of coconut glucoside and 2 parts of cetearyl alcohol polyether are added to 40 parts of an oil phase pre-formulation system, and stirred at 45°C and 500 rpm for 30 minutes to form a uniform oil phase; the oil phase pre-formulation system is composed of caprylic acid triglyceride and triglyceride in a mass ratio of 1:1, that is, 20 parts of caprylic acid triglyceride and 20 parts of triglyceride respectively;

[0056] The uniform aqueous phase is added to the membrane containing VC ethyl ether, and then sheared at a shear rate of 8000 rpm for 10 minutes and then placed in a cell disruptor for 10 minutes to obtain liposome colostrum;

[0057] The uniform oil phase is added dropwise to the liposome colostrum, and after being mechanically stirred uniformly at a stirring speed of 1500 rpm during the dropping process, shearing is performed at a shearing speed of 800 rpm for 5 minutes to obtain a mixed liposome colostrum; the mixed liposome colostrum is subjected to ultrasonic treatment at an ultrasonic temperature of 35° C. for 10 minutes, and then subjected to homogenization circulation treatment at a pressure of 400 bar and a temperature of 45° C., and the mixture is subjected to 5 cycles, and the mixture is cooled to room temperature to obtain a liposome emulsion.

[0058] Example 2

[0059] This example provides an experiment for preparing a transdermal VC ethyl ether liposome emulsion.

[0060] Dissolve 10 parts of VC ethyl ether, 10 parts of resveratrol, 2.5 parts of ascorbyl tetraisopalmitate (VC-IP), 5 parts of ergothioneine, 6 parts of soybean lecithin, 4 parts of egg yolk lecithin and 4 parts of cholesterol in 150 parts of anhydrous ethanol to obtain a mixed solution; then ultrasonicate the mixed solution at a temperature of 56° C. for 50 minutes to make it uniformly dispersed, and then perform thin film rotary evaporation to form a film to remove anhydrous ethanol, so as to obtain a film containing VC ethyl ether;

[0061] 5 parts of VC ethyl ether, 2 parts of hydroxyethyl cellulose, 4 parts of acrylic acid-acrylate copolymer, 70 parts of glycerol, 40 parts of 1,3-propylene glycol and 30 parts of butylene glycol were mixed, and stirred at 55°C and 600 rpm for 40 minutes to form a uniform aqueous phase;

[0062] 8 parts of polyoxyethylene hydrogenated castor oil, 4 parts of cocoyl glucoside and 4 parts of cetearyl alcohol polyether are added to 60 parts of an oil phase pre-formulation system, and stirred at 50°C and 600 rpm for 40 minutes to form a uniform oil phase; the oil phase pre-formulation system is composed of caprylic acid triglyceride and triglyceride in a mass ratio of 1:1, that is, 30 parts of caprylic acid triglyceride and 30 parts of triglyceride respectively;

[0063] The uniform aqueous phase is added to the membrane containing VC ethyl ether, and then sheared at a shear rate of 8500 rpm for 15 minutes, and then placed in a cell disruptor for 15 minutes to obtain liposome colostrum;

[0064] The uniform oil phase is added dropwise to the liposome colostrum, and after being mechanically stirred uniformly at a stirring speed of 1500 rpm during the dropping process, shearing is performed at a shearing speed of 900 rpm for 8 minutes to obtain a mixed liposome colostrum; the mixed liposome colostrum is subjected to ultrasonic treatment at an ultrasonic temperature of 35° C. for 15 minutes, and then subjected to homogenization circulation treatment at a pressure of 400 bar and a temperature of 45° C., and the mixture is subjected to 6 cycles, and then cooled to room temperature to obtain a liposome emulsion.

[0065] Example 3

[0066] This example provides an experiment for preparing a transdermal VC ethyl ether liposome emulsion.

[0067] Dissolve 3 parts of VC ethyl ether, 3 parts of resveratrol, 0.5 parts of ascorbyl tetraisopalmitate (VC-IP), 2 parts of ergothioneine, 2 parts of soybean lecithin, 1 part of egg yolk lecithin and 1 part of cholesterol in 80 parts of anhydrous ethanol to obtain a mixed solution; then ultrasonicate the mixed solution at a temperature of 45° C. for 30 minutes to make it uniformly dispersed, and then perform thin film rotary evaporation to form a film to remove anhydrous ethanol, so as to obtain a film containing VC ethyl ether;

[0068] 5 parts of VC ethyl ether, 0.5 parts of hydroxyethyl cellulose, 1 part of acrylic acid-acrylate copolymer, 30 parts of glycerol, 20 parts of 1,3-propylene glycol and 15 parts of butylene glycol were mixed, and stirred at 400 rpm for 30 minutes at 45°C to form a uniform aqueous phase;

[0069] 4 parts of polyoxyethylene hydrogenated castor oil, 1 part of coconut glucoside and 1 part of cetearyl alcohol polyether are added to 30 parts of an oil phase pre-formulation system, and stirred at 40°C and 400 rpm for 25 minutes to form a uniform oil phase; the oil phase pre-formulation system is composed of caprylic triglyceride and triglyceride in a mass ratio of 1:1, that is, 15 parts of caprylic triglyceride and 15 parts of triglyceride respectively;

[0070] The uniform aqueous phase is added to the membrane containing VC ethyl ether, and then sheared at a shear rate of 7000 rpm for 8 minutes, and then placed in a cell disruptor for 8 minutes to obtain liposome colostrum;

[0071] The uniform oil phase is added dropwise to the liposome colostrum, and after being mechanically stirred uniformly at a stirring speed of 1500 rpm during the dropping process, shearing is performed at a shear speed of 600 rpm for 4 minutes to obtain a mixed liposome colostrum; the mixed liposome colostrum is subjected to ultrasonic treatment at an ultrasonic temperature of 35° C. for 8 minutes, and then subjected to homogenization circulation treatment at a pressure of 400 bar and a temperature of 45° C., and the mixture is subjected to 4 cycles, and then cooled to room temperature to obtain a liposome emulsion.

[0072] Comparative Example 1

[0073] This comparative example provides an experiment for preparing a transdermal VC ethyl ether liposome emulsion.

[0074] Dissolve 5 parts of VC ethyl ether, 5 parts of resveratrol, 1 part of ascorbyl tetraisopalmitate (VC-IP), 3 parts of ergothioneine, 4 parts of soybean lecithin, 2 parts of egg yolk lecithin and 2 parts of cholesterol in 100 parts of anhydrous ethanol to obtain a mixed solution; then ultrasonicate the mixed solution at a power of 100 W and a temperature of 50° C. for 30 minutes to make it uniformly dispersed, and then perform thin film rotary evaporation to remove anhydrous ethanol to obtain a film containing VC ethyl ether;

[0075] 6 parts of polyoxyethylene hydrogenated castor oil, 2 parts of coconut glucoside and 2 parts of cetearyl alcohol polyether are added to 40 parts of an oil phase pre-formulation system, and stirred at 45°C and 500 rpm for 30 minutes to form a uniform oil phase; the oil phase pre-formulation system is composed of caprylic acid triglyceride and triglyceride in a mass ratio of 1:1, that is, 20 parts of caprylic acid triglyceride and 20 parts of triglyceride respectively;

[0076] 10 parts of VC ethyl ether, 1 part of hydroxyethyl cellulose, 2 parts of acrylic acid-acrylate copolymer, 50 parts of glycerol, 30 parts of 1,3-propylene glycol and 20 parts of butanediol were mixed with the film containing VC ethyl ether, and then sheared at 8000 rpm for 10 minutes at 50°C and placed in a cell disruptor for 10 minutes to obtain liposome colostrum;

[0077] The uniform oil phase is added dropwise to the liposome colostrum, and after being mechanically stirred uniformly at a stirring speed of 1500 rpm during the dropping process, shearing is performed at a shearing speed of 800 rpm for 5 minutes to obtain a mixed liposome colostrum; the mixed liposome colostrum is subjected to ultrasonic treatment at an ultrasonic temperature of 35° C. for 10 minutes, and then subjected to homogenization circulation treatment at a pressure of 400 bar and a temperature of 45° C., and the mixture is subjected to 5 cycles, and the mixture is cooled to room temperature to obtain a liposome emulsion.

[0078] Comparative Example 2

[0079] This comparative example provides an experiment for preparing a transdermal VC ethyl ether liposome emulsion.

[0080] Dissolve 5 parts of VC ethyl ether, 1 part of ascorbyl tetraisopalmitate (VC-IP), 3 parts of ergothioneine, 4 parts of soybean lecithin, 2 parts of egg yolk lecithin and 2 parts of cholesterol in 100 parts of anhydrous ethanol to obtain a mixed solution; then ultrasonicate the mixed solution at a power of 100 W and a temperature of 50° C. for 30 minutes to make it uniformly dispersed, and then perform thin film rotary evaporation to remove anhydrous ethanol to obtain a film containing VC ethyl ether;

[0081] 10 parts of VC ethyl ether, 1 part of hydroxyethyl cellulose, 2 parts of acrylic acid-acrylate copolymer, 50 parts of glycerol, 30 parts of 1,3-propylene glycol and 20 parts of butylene glycol were mixed, and stirred at 50°C and 500 rpm for 30 minutes to form a uniform aqueous phase;

[0082] 6 parts of polyoxyethylene hydrogenated castor oil, 2 parts of coconut glucoside and 2 parts of cetearyl alcohol polyether are added to 40 parts of an oil phase pre-formulation system, and stirred at 45°C and 500 rpm for 30 minutes to form a uniform oil phase; the oil phase pre-formulation system is composed of caprylic acid triglyceride and triglyceride in a mass ratio of 1:1, that is, 20 parts of caprylic acid triglyceride and 20 parts of triglyceride respectively;

[0083] The uniform aqueous phase is added to the membrane containing VC ethyl ether, and then sheared at a shear rate of 8000 rpm for 10 minutes and then placed in a cell disruptor for 10 minutes to obtain liposome colostrum;

[0084] The uniform oil phase is added dropwise to the liposome colostrum, and after being mechanically stirred uniformly at a stirring speed of 1500 rpm during the dropping process, shearing is performed at a shearing speed of 800 rpm for 5 minutes to obtain a mixed liposome colostrum; the mixed liposome colostrum is subjected to ultrasonic treatment at an ultrasonic temperature of 35° C. for 10 minutes, and then subjected to homogenization circulation treatment at a pressure of 400 bar and a temperature of 45° C., and the mixture is subjected to 5 cycles, and the mixture is cooled to room temperature to obtain a liposome emulsion.

[0085] Comparative Example 3

[0086] This example provides an experiment for preparing a transdermal VC ethyl ether liposome emulsion.

[0087] Dissolve 5 parts of VC ethyl ether, 5 parts of resveratrol, 3 parts of ergothioneine, 4 parts of soybean lecithin, 2 parts of egg yolk lecithin and 2 parts of cholesterol in 100 parts of anhydrous ethanol to obtain a mixed solution; then ultrasonicate the mixed solution at a power of 100 W and a temperature of 50° C. for 30 minutes to make it uniformly dispersed, and then perform thin film rotary evaporation to remove anhydrous ethanol to obtain a film containing VC ethyl ether;

[0088] 10 parts of VC ethyl ether, 1 part of hydroxyethyl cellulose, 2 parts of acrylic acid-acrylate copolymer, 50 parts of glycerol, 30 parts of 1,3-propylene glycol and 20 parts of butylene glycol were mixed, and stirred at 50°C and 500 rpm for 30 minutes to form a uniform aqueous phase;

[0089] 6 parts of polyoxyethylene hydrogenated castor oil, 2 parts of coconut glucoside and 2 parts of cetearyl alcohol polyether are added to 40 parts of an oil phase pre-formulation system, and stirred at 45°C and 500 rpm for 30 minutes to form a uniform oil phase; the oil phase pre-formulation system is composed of caprylic acid triglyceride and triglyceride in a mass ratio of 1:1, that is, 20 parts of caprylic acid triglyceride and 20 parts of triglyceride respectively;

[0090] The uniform aqueous phase is added to the membrane containing VC ethyl ether, and then sheared at a shear rate of 8000 rpm for 10 minutes and then placed in a cell disruptor for 10 minutes to obtain liposome colostrum;

[0091] The uniform oil phase is added dropwise to the liposome colostrum, and after being mechanically stirred uniformly at a stirring speed of 1500 rpm during the dropping process, shearing is performed at a shearing speed of 800 rpm for 5 minutes to obtain a mixed liposome colostrum; the mixed liposome colostrum is subjected to ultrasonic treatment at an ultrasonic temperature of 35° C. for 10 minutes, and then subjected to homogenization circulation treatment at a pressure of 400 bar and a temperature of 45° C., and the mixture is subjected to 5 cycles, and the mixture is cooled to room temperature to obtain a liposome emulsion.

[0092] Comparative Example 4

[0093] This comparative example provides an experiment for preparing a transdermal VC ethyl ether liposome emulsion.

[0094] Dissolve 5 parts of VC ethyl ether, 5 parts of resveratrol, 1 part of ascorbyl tetraisopalmitate (VC-IP), 4 parts of soybean lecithin, 2 parts of egg yolk lecithin and 2 parts of cholesterol in 100 parts of anhydrous ethanol to obtain a mixed solution; then ultrasonicate the mixed solution at a power of 100 W and a temperature of 50° C. for 30 minutes to make it uniformly dispersed, and then perform thin film rotary evaporation to remove anhydrous ethanol to obtain a film containing VC ethyl ether;

[0095] 10 parts of VC ethyl ether, 1 part of hydroxyethyl cellulose, 2 parts of acrylic acid-acrylate copolymer, 50 parts of glycerol, 30 parts of 1,3-propylene glycol and 20 parts of butylene glycol were mixed, and stirred at 50°C and 500 rpm for 30 minutes to form a uniform aqueous phase;

[0096] 6 parts of polyoxyethylene hydrogenated castor oil, 2 parts of coconut glucoside and 2 parts of cetearyl alcohol polyether are added to 40 parts of an oil phase pre-formulation system, and stirred at 45°C and 500 rpm for 30 minutes to form a uniform oil phase; the oil phase pre-formulation system is composed of caprylic acid triglyceride and triglyceride in a mass ratio of 1:1, that is, 20 parts of caprylic acid triglyceride and 20 parts of triglyceride respectively;

[0097] The uniform aqueous phase is added to the membrane containing VC ethyl ether, and then sheared at a shear rate of 8000 rpm for 10 minutes and then placed in a cell disruptor for 10 minutes to obtain liposome colostrum;

[0098] The uniform oil phase is added dropwise to the liposome colostrum, and after being mechanically stirred uniformly at a stirring speed of 1500 rpm during the dropping process, shearing is performed at a shearing speed of 800 rpm for 5 minutes to obtain a mixed liposome colostrum; the mixed liposome colostrum is subjected to ultrasonic treatment at an ultrasonic temperature of 35° C. for 10 minutes, and then subjected to homogenization circulation treatment at a pressure of 400 bar and a temperature of 45° C., and the mixture is subjected to 5 cycles, and the mixture is cooled to room temperature to obtain a liposome emulsion.

[0099] Comparative Example 5

[0100] This comparative example provides an experiment for preparing a transdermal VC ethyl ether liposome emulsion.

[0101] Dissolve 5 parts of VC ethyl ether, 4 parts of soybean lecithin, 2 parts of egg yolk lecithin and 2 parts of cholesterol in 100 parts of anhydrous ethanol to obtain a mixed solution; then ultrasonicate the mixed solution at a power of 100 W and a temperature of 50° C. for 30 minutes to make it uniformly dispersed, and then perform thin film rotary evaporation to remove the anhydrous ethanol to obtain a film containing VC ethyl ether;

[0102] 10 parts of VC ethyl ether, 1 part of hydroxyethyl cellulose, 2 parts of acrylic acid-acrylate copolymer, 50 parts of glycerol, 30 parts of 1,3-propylene glycol and 20 parts of butylene glycol were mixed, and stirred at 50°C and 500 rpm for 30 minutes to form a uniform aqueous phase;

[0103] 6 parts of polyoxyethylene hydrogenated castor oil, 2 parts of coconut glucoside and 2 parts of cetearyl alcohol polyether are added to 40 parts of an oil phase pre-formulation system, and stirred at 45°C and 500 rpm for 30 minutes to form a uniform oil phase; the oil phase pre-formulation system is composed of caprylic acid triglyceride and triglyceride in a mass ratio of 1:1, that is, 20 parts of caprylic acid triglyceride and 20 parts of triglyceride respectively;

[0104] The uniform aqueous phase is added to the membrane containing VC ethyl ether, and then sheared at a shear rate of 8000 rpm for 10 minutes and then placed in a cell disruptor for 10 minutes to obtain liposome colostrum;

[0105] The uniform oil phase is added dropwise to the liposome colostrum, and after being mechanically stirred uniformly at a stirring speed of 1500 rpm during the dropping process, shearing is performed at a shearing speed of 800 rpm for 5 minutes to obtain a mixed liposome colostrum; the mixed liposome colostrum is subjected to ultrasonic treatment at an ultrasonic temperature of 35° C. for 10 minutes, and then subjected to homogenization circulation treatment at a pressure of 400 bar and a temperature of 45° C., and the mixture is subjected to 5 cycles, and the mixture is cooled to room temperature to obtain a liposome emulsion.

[0106] Test Example 1

[0107] This test example provides a particle size stability test experiment of a transdermal VC ethyl ether liposome emulsion.

[0108] The samples were placed in a sealed container at -18°C, 4°C, room temperature and 45°C for 180 days. The particle sizes of the samples were tested at the initial state and after 180 days at room temperature.

[0109] In this test example, the liposome emulsions prepared in Examples 1-3 and Comparative Examples 1-5 were used as samples, and the particle size of each sample was measured to obtain the results. The results obtained by measurement are shown in Table 1.

[0110] Table 1 Particle size stability test

[0111]

[0112] As shown in Table 1, the liposome emulsions prepared in Example 1 and Comparative Example 2 exhibit good stability. The particle size variation of the liposome emulsions prepared in Example 3, Example 2, Comparative Example 5, Comparative Example 3, Comparative Example 1, and Comparative Example 4 increases in sequence, and the particle size stability decreases in sequence. The particle size and particle size variation of the liposome emulsion prepared in Example 1 are the smallest, and the system is the most stable.

[0113] Test Example 2

[0114] This test example provides an ABTS free radical scavenging experiment of a transdermal VC ethyl ether liposome emulsion.

[0115] Dilute the sample to a final concentration of VC ethyl ether of 10 mg / ml, take 10 μl of the sample to be tested and mix it with 190 μl of 0.25 mmol / LABTS working solution / PBS, shake it thoroughly, incubate it at room temperature for 6 minutes, and measure the absorbance at 405 nm. The absorbance of the sample to be tested and the ABTS working solution is recorded as A1, the absorbance of the sample to be tested and PBS is recorded as A2, and the absorbance of the ABTS working solution and PBS is recorded as A3. Then the ABTS clearance rate = [1-(A1-A2) / A3]×100%. The positive control is vitamin C with a sample concentration of 200, 150, 125, 100, 75, 50, and 25 μg / mL. The IC50 of the positive control VC is between 0.040 g / L and 0.070 g / L, and the test system is considered to be effective. Repeat three times.

[0116] In this test example, the liposome emulsions prepared in Examples 1-3 and Comparative Examples 1-5 were used as test samples to conduct ABTS free radical scavenging experiments to obtain the free radical scavenging rates of each liposome emulsion. The results are shown in Table 2. The average free radical scavenging rates measured three times were taken, and the results were as follows: Figure 1 shown.

[0117] Table 2 ABTS free radical scavenging rate

[0118]

[0119] From Table 2 and Figure 1 It can be seen that the ABTS free radical scavenging rate of the liposome emulsion prepared in Example 1 is the highest, with an average value of 68.37%, followed by Example 2 and Example 3. The ABTS free radical scavenging rates of the liposome emulsions prepared in Comparative Examples 1-4 decrease in sequence, indicating that the liposome emulsion provided by the present invention can effectively scavenge free radicals.

[0120] Test Example 3

[0121] This test example provides a tyrosinase activity inhibition experiment of a transdermal VC ethyl ether liposome emulsion.

[0122] Mix 80 μL of PBS buffer, 40 μL of the sample to be tested, 40 μL of tyrosinase solution and 80 μL of substrate L-tyrosine solution, and incubate at 25°C in the dark for 20 minutes as the sample reaction group. Mix 160 μL of PBS buffer, 40 μL of the sample to be tested, and 40 μL of tyrosinase solution, and incubate at 25°C in the dark for 20 minutes as the sample blank group. Mix 80 μL of PBS buffer, 40 μL of pure water, 40 μL of tyrosinase solution and 80 μL of substrate L-tyrosine solution, and incubate at 25°C in the dark for 20 minutes as the negative reaction group. Mix 160 μL of PBS buffer, 40 μL of pure water, and 40 μL of tyrosinase solution, and incubate at 25°C in the dark for 20 minutes as the negative blank group. The absorbance of each group was detected at 475 nm by an ELISA instrument (each group was tested three times in parallel and the average value was taken), and the effect of the sample on the activity of tyrosinase was calculated and the statistical difference P value was calculated. The absorbance of the negative reaction group was recorded as A0, the absorbance of the negative blank group was recorded as A1, the absorbance of the sample reaction group was recorded as B0, and the absorbance of the sample blank group was recorded as B1. Tyrosinase inhibition rate = [1-(B0-B1) / (A0-A1)]×100%.

[0123] In this test example, the liposome emulsions prepared in Examples 1-3 and Comparative Examples 1-5 were used as test samples to perform a tyrosinase activity inhibition experiment to obtain the tyrosinase inhibition rate of each liposome emulsion. The results are shown in Table 3. The average of the tyrosinase inhibition rates measured three times was taken. The results are shown in Table 3. Figure 2 shown.

[0124] Table 3 Tyrosinase inhibition rate

[0125]

[0126] From Table 3 and Figure 2 It can be obtained that the liposome emulsion prepared in Example 1 has the highest tyrosinase inhibition rate, with an average value of 71.56%, followed by the liposome emulsion prepared in Example 3, with an average value of 66.77%. The tyrosinase inhibition rates of Comparative Example 3, Example 2, Comparative Example 5, Comparative Example 1, Comparative Example 4, and Comparative Example 2 decrease in sequence. The liposome emulsion prepared in Example 1 has the best inhibitory effect on tyrosinase. It is illustrated that the tyrosinase activity provided by the present invention can be effectively inhibited.

[0127] Test Example 4

[0128] This test example provides an experiment on the inhibition of melanin formation by a transdermal VC ethyl ether liposome emulsion.

[0129] B16F10 cells (melanoma cells) in the logarithmic growth phase were cultured at 3×10 3Each well was inoculated in a 96-well plate, with a system of 100 μL in each well. The outermost circle of the 96-well plate was sealed with 100 μL of PBS. After 24 hours, when the cells were completely attached to the wall, they were replaced with complete culture medium containing the sample to be tested or a blank control group containing only complete culture medium (blank control). After continuing to culture the cells for 48 hours, the cell activity was detected by CCK-8 method at a detection wavelength of 450 nm. Repeat three times.

[0130] In this test example, the liposome emulsions prepared in Examples 1-3 and Comparative Examples 1-5 were diluted with DMEM complete medium at a final concentration of 10% by mass to obtain a complete medium containing the sample to be tested, and a melanin formation inhibition experiment was performed to obtain the inhibition rate of each liposome emulsion on B16F10 cells (melanoma cells). The results are shown in Table 4. The average value of the three measurements of B16F10 cells (melanoma cells) was taken. The results are shown in Table 4. Figure 3 shown.

[0131] Table 4 Melanoma cell inhibition rate

[0132]

[0133]

[0134] From Table 4 and Figure 3 It can be obtained that the liposome emulsion prepared in Example 1 has the best inhibitory effect on B16F10 cells, with an average inhibition rate of 65.12%, followed by the liposome emulsion prepared in Example 3, with an average inhibition rate of 60.75% on B16F10 cells. The inhibition rates of the liposome emulsions prepared in Comparative Example 3, Example 2, Comparative Example 1, Comparative Example 2, Comparative Example 4, and Comparative Example 5 on B16F10 cells decrease in sequence. It is shown that the liposome emulsion provided by the present invention can effectively inhibit the formation of melanin.

[0135] Test Example 5

[0136] This test example provides an in vitro percutaneous absorption test experiment of a percutaneous VC ethyl ether liposome emulsion.

[0137] A Franz vertical diffusion cell was used, and the skin of an isolated SD male rat was used as a transdermal barrier. The skin was fixed between the supply chamber and the receiving chamber of the Franz diffusion cell, and the effective transdermal area of ​​the stratum corneum facing the supply chamber was 0.8 cm2. The sample was added to the supply chamber, and the receiving solution was a 20% ethanol PBS solution with a volume of 8 mL. The temperature of the transdermal diffusion instrument was 37±1°C and the speed was 500 rpm / min. 0.5 mL of the receiving solution was sampled at 2h, 4h, 8h, and 24h to determine the transdermal amount of VC ethyl ether. After each sampling, the same volume of fresh receiving solution was added and care was taken to prevent the introduction of bubbles. After sampling, the sample was filtered at 0.25 μm and the content was determined by high performance liquid chromatography HPLC. The cumulative transdermal amount Q was calculated using the formula shown in (1).

[0138]

[0139] Where: C n is the sample concentration measured at the nth sampling point (μg / mL); Ci is the sample concentration measured at the ith (i=n-1)th sampling point; 8 is the total volume of the receiving solution (mL); 0.5 is the sampling volume (mL); 0.8 is the effective skin penetration area cm 2 .

[0140] In this test example, the liposome emulsions prepared in Examples 1-3 and Comparative Examples 1-5 were used as samples for in vitro transdermal absorption tests. The results are shown in Tables 5 and Figure 4 Shown

[0141] Table 5 Cumulative transdermal amount at each time point

[0142]

[0143] From Table 5 and Figure 4 It can be seen that, compared with Comparative Examples 1-5, the liposome emulsions prepared in Examples 1-3 and , have a higher transdermal absorption of VC ethyl ether, indicating that the liposome emulsion provided by the present invention has an effect of significantly improving the transdermal absorption of VC ethyl ether.

[0144] Application Example 1

[0145] This application example provides an experiment for preparing a lotion.

[0146] In terms of mass ratio, 2 parts of hyaluronic acid and 1 part of glycerol were stirred at 50° C. and 300 rpm for 30 minutes to uniformly dissolve them in 46 parts of purified water to obtain solution a;

[0147] Dissolve 5 parts of liposome emulsion and 1 part of water-soluble silicone oil in 45 parts of pure water at 30°C and 500 rpm, and stir at 300 rpm to obtain solution b; the liposome emulsion is the liposome emulsion prepared in Example 1;

[0148] After the temperature of solution a was lowered to 30° C., solution a was added to solution b and stirred at 30° C. and 300 rpm for 30 min to obtain a lotion.

[0149] This application example provides a mouse skin irritation experiment of the lotion:

[0150] 24 hours before the experiment, the experimental mice (purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd.) were shaved on both sides of the spine and then depilated. The depilation range was 3cm×3cm on the left and right sides. 0.5g of the test substance was directly applied to the skin on the right side of the back (experimental group), then covered with plastic wrap and fixed with non-irritating adhesive tape. The closed test was used and the application time was 4 hours. The skin on the left side of the back was used as the control (blank group).

[0151] After 4 hours, remove the test substance from the right side of the back skin of the experimental mice. After 1 hour, observe the skin reaction of the mice at the application site to see if there is erythema or edema. Figure 5 The skin reaction scores were scored according to Table 6 below, and the comprehensive evaluation was performed based on the scores of the test mice.

[0152] In this application example, the lotion is used as a test substance to conduct a skin irritation experiment.

[0153] Table 6 Skin reaction scoring table

[0154]

[0155] The left skin was used as a control. Figure 5 It was observed that there was no erythema or edema on the right side of the mouse skin, and the mouse skin irritation reaction score was 0, indicating that the lotion provided by the present invention was non-irritating to the mouse skin.

[0156] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.

[0157] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.

Claims

1. A VC ethyl ether liposome emulsion for transdermal absorption, characterized in that: It includes component A, component B and component C; The component A comprises, by weight: 3-10 parts of VC ethyl ether, 3-10 parts of resveratrol, 0.5-2.5 parts of ascorbyl tetraisopalmitate, 2-5 parts of ergothioneine, 4-14 parts of lipids; The B component comprises, by weight: 5-20 parts of VC ethyl ether, 1.5-6 parts of film former, 65-140 parts of auxiliary emulsifier; The C component comprises, by weight: 6-16 parts of emulsifier, 30-60 parts of oil phase pre-formulated system; The oil phase preformulation system consists of caprylic acid triglyceride and triglyceride.

2. The VC ethyl ether liposome emulsion for percutaneous absorption according to claim 1, characterized in that, It includes component A, component B and component C; The component A comprises, by weight: 5 parts of VC ethyl ether, 5 parts of resveratrol, 1 part of ascorbyl tetraisopalmitate, 3 parts of ergothioneine, 8 parts of lipids; The B component comprises, by weight: 10 parts of VC ethyl ether, 3 parts of film former, 100 parts of co-emulsifier; The C component comprises, by weight: 10 parts of emulsifier, 40 parts of oil phase pre-formulated system; The oil phase pre-formulated system consists of caprylic acid triglyceride and triglyceride in a mass ratio of 1:

1.

3. The VC ethyl ether liposome emulsion for percutaneous absorption according to claim 1, characterized in that, The lipid is one or more of lecithin, cholesterol, soybean lecithin, hydrogenated lecithin, egg yolk lecithin, phosphatidylcholine, and phosphatidylserine; And / or, the film-forming agent is one or more of hydroxyethyl cellulose, acrylic acid-acrylate copolymer, L-arabinose, and pullulan. And / or, the auxiliary emulsifier is one or more of glycerol, 1,3-propylene glycol, butylene glycol, 1,2-pentanediol, sorbitol, 1,2-hexanediol, dipropylene glycol, butylene glycol laureth-23, PPG-26-butylene glycol polyether-26, trideceth-12, and hexyldecanol; And / or, the emulsifier is one or more of polyoxyethylene hydrogenated castor oil, coco-glucoside, cetearyl alcohol polyether, polyglyceryl-10 stearate, PEG-8 caprylic / capric glyceride, sucrose stearate, sodium alkylbenzene sulfonate, and PEG-40 hydrogenated castor oil.

4. A method for preparing a transdermal VC ethyl ether liposome emulsion according to any one of claims 1 to 3, characterized in that: The following steps are involved: Dissolving the VC ethyl ether, the resveratrol, the ascorbyl tetraisopalmitate, the ergothioneine and the lipid in an organic solvent to obtain the A component; The VC ethyl ether, the film-forming agent and the co-emulsifier are uniformly mixed to obtain the B component; Adding the emulsifier to the oil phase preformulation system to obtain the C component; adding the B component to the A component to obtain liposome colostrum; The C component is added to the liposome colostrum, and the mixture is subjected to stirring, shearing, ultrasonication, homogenization circulation treatment and cooling to room temperature to obtain the transdermal VC ethyl ether liposome emulsion.

5. The method for preparing the VC ethyl ether liposome emulsion for transdermal absorption according to claim 4, characterized in that, The preparation conditions of the A component are: ultrasonic treatment at 45-56°C for 30-50min; And / or, the preparation conditions of the B component are: stirring at 400-600 rpm for 30-40 min at 45-55°C; And / or, the preparation conditions of the C component are: stirring at 400-600 rpm for 25-40 min at 40-50° C.; And / or, the preparation conditions of the liposome colostrum are: shearing at a shear rate of 7000-8500 rpm for 8-15 min; And / or, the number of cycles of the homogenization cycle treatment is 4-6 times.

6. Use of the transdermal VC ethyl ether liposome emulsion according to any one of claims 1 to 3 in the preparation of antioxidants and / or melanoma cell inhibitors.

7. Use of the transdermal VC ethyl ether liposome emulsion according to claim 6 in the preparation of antioxidants and / or melanoma cell inhibitors, characterized in that: The transdermal VC ethyl ether liposome emulsion is used to scavenge free radical activity; And / or, the transdermal VC ethyl ether liposome emulsion is used to inhibit melanoma cell proliferation.

8. Use of the transdermal VC ethyl ether liposome emulsion according to claim 7 in the preparation of antioxidants and / or inhibitors of melanoma cells, characterized in that: The transdermal VC ethyl ether liposome emulsion can also be used to inhibit tyrosinase activity.

9. Use of the transdermal VC ethyl ether liposome emulsion according to any one of claims 1 to 3 in the preparation of cosmetics.

10. A cosmetic, characterized in that: The invention relates to a VC ethyl ether liposome emulsion for transdermal absorption comprising the VC ethyl ether liposome emulsion according to any one of claims 1 to 3.

Citation Information

Patent Citations

  • Composite functional liposome and preparation method and application thereof

    CN101816632A

  • Hydroxy asiaticoside liposome as well as preparation method and application thereof

    CN109431829A

  • Preparation method of low-ester pectin stabilized composite phospholipid liposome

    CN109498576A

  • Quintuple VC (Vitamin C) composition with whitening effect

    CN116785195A

  • Transdermal absorption anti-aging liposome composition as well as preparation method and application thereof

    CN118680836A